<DOC>
	<DOC>NCT00372372</DOC>
	<brief_summary>The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment</brief_summary>
	<brief_title>The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment</brief_title>
	<detailed_description>We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>1. Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (&gt;=0.8mg/kg/day) or equivalent for at least 6 weeks. 2. Age&gt;=18 years and &lt;75 years. 1. Pregnant or lactating women. 2. Uncorrected hypocalcemia. 3. History of esophageal stricture. 4. Previous intolerance or hypersenstivity to biphosphonates.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>corticosteroids, bone mineral, risedronate, bisphosphonate</keyword>
</DOC>